liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients
Department of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center, Huoston. TX.
Linköping University, Department of Biomedicine and Surgery, Oncology. Linköping University, Faculty of Health Sciences.
Show others and affiliations
2006 (English)In: Journal of the National Cancer Institute, ISSN 0027-8874, E-ISSN 1460-2105, Vol. 98, no 10, 671-680 p.Article in journal (Refereed) Published
Abstract [en]

Background: p21-activated kinase 1 (Pak1) phosphorylates many proteins in both normal and transformed cells. Its ability to phosphorylate and thereby activate the estrogen receptor α (ERα) potentially limits the effectiveness of antiestrogen treatment in breast cancer. Here we studied associations between Pak1 expression and subcellular localization in tumor cells and tamoxifen resistance.

Methods: Pak1 protein expression was evaluated in 403 primary breast tumors from premenopausal patients who had been randomly assigned to 2 years of adjuvant tamoxifen or no treatment. Tamoxifen response was evaluated by comparing recurrence-free survival in relation to Pak1 and ERα expression in untreated versus tamoxifen-treated patients. Tamoxifen responsiveness of human MCF-7 breast cancer cells that inducibly expressed constitutively active Pak1 or that transiently overexpressed wild-type Pak1 (Wt-Pak1) or Pak1 that lacked functional nuclear localization signals (Pak1ΔNLS) was evaluated by analyzing cyclin D1 promoter activation and protein levels as markers for ERα activation. The response to tamoxifen in relation to Pak1 expression was analyzed in naturally tamoxifen-resistant Ishikawa human endometrial cancer cells. All statistical tests were two-sided.

Results: Among patients who had ERα–positive tumors with low Pak1 expression, those treated with tamoxifen had better recurrence-free survival than those who received no treatment (hazard ratio [HR] = 0.502, 95% confidence interval [CI] = 0.331 to 0.762; P = .001) whereas there was no difference in recurrence-free survival between treatment groups for patients whose tumors had high cytoplasmic (HR = 0.893, 95% CI = 0.420 to 1.901; P = .769) or any nuclear Pak1 expression (HR = 0.955, 95% CI = 0.405 to 2.250; P = .916). In MCF-7 cells, overexpression of Wt-Pak1, but not of Pak1ΔNLS, compromised tamoxifen response by stimulating cyclin D1 expression. Treatment of Ishikawa cells with tamoxifen led to an increase in the amount of nuclear Pak1 and Pak1 kinase activity, suggesting that tamoxifen, to some extent, regulates Pak1 expression.

Conclusions: Our data support a role for Pak1, particular Pak1 localized to the nucleus, in ERα signaling and in tamoxifen resistance.

Place, publisher, year, edition, pages
2006. Vol. 98, no 10, 671-680 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-36105DOI: 10.1093/jnci/djj185Local ID: 29907OAI: diva2:256953
Available from: 2009-10-10 Created: 2009-10-10 Last updated: 2013-01-16

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Stål, Olle
By organisation
OncologyFaculty of Health Sciences
In the same journal
Journal of the National Cancer Institute
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 14 hits
ReferencesLink to record
Permanent link

Direct link